Polycystic Ovary Syndrome Treatment Using DLBS3233, Metformin, and Combination of Both, and Its Relation to Fertility

Trial Profile

Polycystic Ovary Syndrome Treatment Using DLBS3233, Metformin, and Combination of Both, and Its Relation to Fertility

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 May 2017

At a glance

  • Drugs DLBS 3233 (Primary) ; Metformin
  • Indications Insulin resistance; Polycystic ovary syndrome
  • Focus Therapeutic Use
  • Acronyms POSITIF
  • Sponsors Dexa Medica
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Oct 2018.
    • 02 May 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top